Core outcome sets for myocardial infarction in clinical trials of traditional Chinese medicine and Western medicine

医学 心肌梗塞 临床试验 随机对照试验 心绞痛 德尔菲法 内科学 物理疗法 家庭医学 重症监护医学 数学 统计
作者
Ruijin Qiu,Siqi Wan,Changming Zhong,Songjie Han,Tianmai He,Ya Huang,Xuxu Wei,Meng Li,Zhiyue Guan,Xinyi Zhang,Huanlin Wu,Hongcai Shang
出处
期刊:Journal of Evidence-based Medicine [Wiley]
卷期号:17 (1): 86-94 被引量:6
标识
DOI:10.1111/jebm.12579
摘要

BACKGROUND: Clinical trials of traditional Chinese medicine (TCM) and Western medicine showed there was heterogeneity of outcome reporting in myocardial infarction (MI). Developing a core outcome set (COS) might improve the consistency of outcome reporting in future clinical trials. METHODS: A list of outcomes was developed based on a systematic review of randomized controlled trials (RCTs) of MI and semistructured interviews with MI patients. Two rounds of Delphi survey for clinicians, researchers, journal editors, and methodologists were conducted. An online questionnaire sent to nurses. After an online consensus meeting, a COS for MI RCTs was developed. RESULTS: After extracted data from clinical trials and discussed, 216 outcomes were included in round 1 of the Delphi survey. Seventy-four participants completed round 1 of the Delphi survey. Sixty-five participants completed round 2 of the Delphi survey. Twenty-two nurses completed the online questionnaire. Fifteen participants attended the online consensus meeting, and 14 of them voted and determined the final COS. For all types of MI, it was recommended that left ventricular ejection fraction and quality of life be measured and reported. For acute MI, the participants in the consensus meeting recommended the following core outcomes: death from cardio-cerebrovascular disease, cardiogenic shock, heart failure, troponin I, troponin T, creatine kinase isoenzyme, Killip class, target vessel revascularization, and emergency CABG. For previous MI, recurrent MI, recurrent angina pectoris, and heart failure readmission were recommended. CONCLUSIONS: The COS for MI in RCTs provides recommendations for clinical trials that seek to improve outcomes for patients with MI.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
专注新晴完成签到,获得积分10
刚刚
刚刚
刚刚
喵喵酱完成签到,获得积分10
刚刚
Sarah完成签到 ,获得积分10
刚刚
甲灯灯完成签到,获得积分10
刚刚
小马甲应助王豆豆采纳,获得30
刚刚
1秒前
彪壮的冬日完成签到,获得积分10
2秒前
认真的小虾米完成签到 ,获得积分10
2秒前
2秒前
2秒前
sev发布了新的文献求助10
2秒前
万能图书馆应助花海采纳,获得10
3秒前
4秒前
冰_发布了新的文献求助10
5秒前
冷静的不言完成签到,获得积分10
6秒前
7秒前
luoshiwen发布了新的文献求助100
8秒前
9秒前
灰色头像完成签到,获得积分10
9秒前
9秒前
马嘎嘎发布了新的文献求助10
10秒前
共享精神应助苏沐阳采纳,获得10
10秒前
小张发布了新的文献求助10
11秒前
无私妙菡发布了新的文献求助10
11秒前
鸢一折纸发布了新的文献求助10
12秒前
12秒前
12秒前
12秒前
12秒前
14秒前
14秒前
panpan完成签到,获得积分10
14秒前
15秒前
黄小小发布了新的文献求助10
15秒前
15秒前
15秒前
16秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Prompt Engineering for Clinicians: Harnessing AI in Everyday Medical Practice 600
Electrode Potentials 550
REAL-WORLD EFFICACY AND GENOMIC LANDSCAPE OF POLATUZUMA VEDOTIN-BASED FIRST-LINE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA: A FOCUS ON TP53 MUTATIONS AND TREATMENT RESPONSE 500
Handbook of Luminescence Dating 500
Safety Pharmacology 500
《KNN基无铅压电陶瓷电学性能优化与物理机理研究》 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 计算机科学 化学工程 生物化学 物理 内科学 复合材料 催化作用 光电子学 物理化学 电极 细胞生物学 基因 遗传学
热门帖子
关注 科研通微信公众号,转发送积分 6962082
求助须知:如何正确求助?哪些是违规求助? 8644442
关于积分的说明 18332056
捐赠科研通 6411697
什么是DOI,文献DOI怎么找? 3086215
关于科研通互助平台的介绍 2135161
邀请新用户注册赠送积分活动 2062717